Pinealon
EDR peptide Β· Glu-Asp-Arg Β· Cortagen (related)
Short tripeptide (Glu-Asp-Arg) isolated from the pineal gland by Russian researchers (Khavinson et al.). Exhibits neuroprotective and geroprotective effects in animal and limited human studies, primarily through restoration of pineal and CNS gene expression patterns.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Penetrates the blood-brain barrier (small size). Binds specific DNA sequences in neuronal chromatin, activating transcription of neuroprotective genes including antioxidant enzymes, BDNF, and melatonin synthesis pathway genes. Reduces neuronal apoptosis and oxidative stress. Restores circadian clock gene expression (CLOCK, BMAL1) that is dysregulated with age.
Clinical Applications
- βAge-related cognitive decline and neuroprotection
- βSleep quality restoration β circadian clock gene normalisation
- βRetinal degeneration support (pineal-retinal connection)
- βStress-induced neurological damage recovery
- βLongevity and geroprotection as part of peptide bioregulator stacks
- βPost-stroke or TBI neurological recovery (investigational)
Dosing Protocol
Recommended Dosing
SC injection or intranasal. SC: 0.1β0.3 mg daily for 10 days, 1β2 courses per year. Intranasal: 0.1 mg per nostril, 2Γ daily for 10 days. Often stacked with other Khavinson peptides (Epithalon, Vilon, Thymalin). Long half-life effects despite short peptide β effects on gene expression persist weeks after dosing cycle ends.Safety & Contraindications
Possible Side Effects
- β Generally very well tolerated β limited adverse event reporting
- β Injection site reactions (minimal)
- β Intranasal: occasional mild nasal irritation
- β Excessive sedation at high doses (melatonin pathway upregulation)
Contraindications
- βPregnancy
- βSevere depression or bipolar disorder (melatonin pathway modulation may destabilise)
- βConcurrent melatonin supplementation >3 mg/day (additive sedation risk)